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Ang II is shown to mediate the stimulatory eﬀect of high glucose on TGF-b1 and extracellular matrix proteins in glomerular
mesangial cells. Also inhibition of Ang II formation in cell media (extracellular) and lysates (intracellular) blocks high-glucose
eﬀects on TGF-b1 and matrix more eﬀectively compared to inhibition of extracellular Ang II alone. To investigate whether intra-
cellular Ang II can stimulate TGF-b1 and matrix independent of extracellular Ang II, cultured human mesangial cells were trans-
fected with Ang II to increase intracellular Ang II levels and its eﬀects on TGF-b1 and matrix proteins were determined. Prior to
transfection, cells were treated with candesartan to block extracellular Ang II-induced responses via cell membrane AT1 receptors.
Transfectionofcells withAngIIresulted inincreased levelsofintracellularAngIIwhichwasaccompaniedby increasedproduction
ofTGF-b1,collagenIV,ﬁbronectin,andcell proliferationaswell.Onfurtherexamination,intracellularAngIIwasfoundtoactivate
Stat3 transcription factor including increased Stat3 protein expression, tyrosine 705 phosphorylation, and DNA-binding activity.
Treatment with AG-490, an inhibitor of Jak2, did not block intracellular Ang II-induced Stat3 phosphorylation at tyrosine 705
residue indicating a Jak2-independentmechanismused by intracellular Ang II forStat3 phosphorylation.In contrast,extracellular
Ang II-induced tyrosine 705 phosphorylation of Stat3 was inhibited by AG-490 conﬁrming the presence of a Jak2-dependent
pathway. These ﬁndings suggest that intracellular Ang II increases TGF-b1 and matrix in human mesangial cells and also activates
Stat3 transcription factor without involvement of the extracellular Ang II signalingpathway.
1.Introduction
Kidneydamage is one ofthe long-termcomplicationsof dia-
betes(diabeticnephropathy)which ischaracterized byexces-
siveproductionofextracellularmatrix byglomerularmesan-
gial cells. Angiotensin II (Ang II), a growth-promoting hor-
mone derived from the renin angiotensin system (RAS), is
suggested to play an important role in transmitting high
glucose eﬀects on mesangial matrix [1]. Similar to glucose,
Ang II increases matrix synthesis [2]a n dd e c r e a s e sm a t r i x
degradation[3]leadingtomatrix accumulationinmesangial
cells. Bothglucoseand AngII appeartoinvolvetransforming
growthfactor-beta 1(TGF-b1)for theiractionsonmesangial
matrix. Previous studies have reported that high glucose
causes increase in TGF-b1 mRNA expression and protein in
mesangial cells [4, 5].Also, Ang IIis found tostimulate TGF-
b1 secretion in rat mesangial cells as demonstrated by our
previousstudies[3].BecausetheseactionsofAngIIare simi-
lar to those of glucose, it is likely that Ang II may act as a
downstream mediatorofhigh-glucoseeﬀectsonTGF-b1and
matrix in mesangial cells.
It is now well established that high-glucose milieu in
diabetes causes activation of the RAS, particularly Ang II
[1]. Treatment with angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) has
provenbeneﬁcialindelayingtheprogression ofrenaldamage
in type1and type2diabeticpatients[6–8]suggesting activa-
tion of the RAS due to hyperglycemia. An increased renal
vasodilator response to ACE inhibition or Ang II blockade
in diabetic patients [9] has been interpreted as evidence that
the intrarenal RASis activated in diabetes. In streptozotocin-
(STZ-) induced rat model of diabetes (type 1), we found
increased levels of Ang II and its precursor, angiotensinogen
(Agt) in glomerular extracts indicating activation of the
glomerular RAS [10]. Also in type 2 diabetic rats, blockade
of Ang II activity by ACE inhibitors and ARBs ameliorated2 Journal of Signal Transduction
progression of proteinuria and preserved glomerular struc-
ture further supporting RAS activation in diabetes [11].
Previous studies from our laboratory have consistently
shown that high glucose activates Ang II production in
mesangial cells [3, 12, 13] primarily by increasing synthesis
of Agt, the precursor of Ang II [12]. In addition, exposure of
mesangial cells to high glucose resulted in increased levels of
Ang IIin thecell lysates(intracellular) which were noticeably
higher compared to extracellular Ang II levels found in the
cell media [14, 15]. Further, our recent studies showed that
inhibition of extracellular Ang II formation resulted in a par-
tial block of high-glucose-induced increase in TGF-b1
and matrix, whereas suppression of both intracellular and
extracellular Ang II formation by Agt knockdown pro-
duced a greater inhibition of TGF-b1 and matrix [15]. These
ﬁndings led us to hypothesize that intracellular Ang II may
contribute to the overall increase in TGF-b1 and mesan-
gial matrix proteins under high-glucose condition. There-
fore, the present study was designed to investigate whether
intracellular Ang II can independently aﬀect TGF-b1 and
matrix in mesangial cells without involvement of the extra-
cellularAngIIsignaling pathway.Culturedhumanmesangial
cells were transfected with Ang II to increase intracellular
Ang II levels whereas candesartan was used to block activa-
tion of extracellular Ang II signaling via the cell membrane
AT1 receptors. The ﬁndings of the present study suggest
that intracellular Ang II can increase TGF-b1 and mesangial
matrix and also activates Stat3 transcription factor inde-
pendent of the extracellular Ang II signaling pathway.
2.Methods
2.1. Chemicals. Angiotensin II was purchased from Sigma
Chemicals (St. Louis, Mo) and angiotensin II conjugated
with ﬂuorescein from Invitrogen (Carlsbad, CA). AG-490
and Jak inhibitor I were obtained from Calbiochem (EMD
Chemicals Inc., Gibbstown, NJ). SDS, acrylamide/Bis, nitro-
cellulose membrane, Tween-20, ammonium persulphate,
TEMED, and protein assay reagents were purchased from
Bio-Radlaboratories(Hercules,CA)andotherreagentsfrom
Sigma Chemicals (St. Louis, MO). Antibodies to total Stat3,
β-actin, and goat anti-rabbit IgG conjugated with horse-
radish peroxidase (HRP) were obtained from Cell Signaling
Technology (Danvers, MA) and anti-Jak2 antibody from
CHEMICON (EMD Millipore, Danvers, MA). The protein
molecular weight marker was obtained from Amersham
(GE Healthcare, Piscataway, NJ) and the chemiluminescence
detection kit from Pierce (Thermo Fisher Scientiﬁc, Rock-
ford, IL). Candesartan was obtained from AstraZeneca Phar-
maceuticals (Wilmington, DE).
2.2. Human Mesangial Cell Culture. Primary normal human
mesangial cells (HMCs) were obtained from ScienCell (CA)
at passage 1 and maintained in mesangial cell growth media
(MsGM)(Lonza,MD)containing5%fetalbovineserumand
1μg/mL gentamicin at 37◦Ci n5 %C O 2 and 95% air [15].
Cells were subcultured at 70–80% conﬂuence, and experi-
ments were performed on cells between 2 and 5 passages.
2.3. Transfection of Cells with Ang II. To study the role of in-
tracellular Ang II speciﬁcally, intracellular levels of Ang II
were increased using a protein transfection reagent (Prote-
o j u i c e ,N o v a g e n ,W I ) .B r i e ﬂ y ,A n gI Iw a sm i x e dw i t hp r o t e -
ojuice as per instructions from the supplier (Novagen) and
incubated for 20min at room temperature followed by
1:10 dilution with MsGM free of serum and supplements.
Mesangial cells were then incubated with this media for 20
minutes to 24h depending upon the experimental protocol.
To inhibit binding of any free Ang II present in the prote-
ojuice mixture to cell membrane AT1 receptors, cells were
pretreated with candesartan to block AT1 receptors. At ter-
mination of experiments, cell media were collected and cells
were used for preparation of either total cell lysates (in RIPA
buﬀer) or cytosol and nuclear fractions (Active Motif, CA).
Samples were stored at −70◦C until analyzed.
2.4. Measurement of Ang II Levels by ELISA. Ang II levels
in cell media (extracellular) and lysates (intracellular) were
measured by a competitive inhibition ELISA (Peninsula-
Bachem, Belmont, CA) as described previously by us [14].
Brieﬂy,standards orsamplesalong with anti-Ang II antibody
and biotinylated Ang II peptide were incubated in a 96-
well plate for 2h followed by incubation with streptavidin-
conjugated horseradish peroxidase for 1h at room temper-
ature. The ﬁnal reaction in the well was developed with
3,3 ,5,5 -tetramethyl benzidine (TMB) substrate, terminated
with 2N HCl, and read at 450nm using an ELISA reader.
Ang II levels in the samples were calculated from an Ang II
standard curve run with each assay.
2.5. Measurement of Matrix Proteins and Cell Proliferation.
Cell media were dialyzed, lyophilized, and reconstituted at a
known protein concentration. TGF-b1 levels were measured
by a sandwich ELISA which employs a primary capture anti-
body and the avidin-biotin peroxidase detection system
(R&D Systems, Minneapolis, MN) [3]. Collagen IV and
ﬁbronectin levels in cell media were measured by ELISA us-
ing commercially available kits from Exocell (Philadelphia,
PA) and CHEMICON (EMD Millipore Danvers, MA), re-
spectively. For determination of cell proliferation, mesangial
cells were seeded in 96-well plates 24–48 prior to the as-
say. Cells were transfected with Ang II using proteojuice
and incubated at 37◦Ci n5 %C O 2 and 95% air for 48h
after which proliferation of cells was measured using a color-
imetric method (Roche Applied Sciences, IN).
2.6. Study of Jak2/Stat3 Pathway
2.6.1. Protein Expression of Jak2 and Stat3. Total cells lysates
from mesangial cells treated with exogenous Ang II or trans-
fected with Ang II were prepared in RIPA buﬀer (Santa Cruz
Biotechnology, CA) and analyzed for protein expression of
Jak2 and Stat3 by Western blotting. Samples were elec-
trophoresed on 8–10% acrylamide gel and proteins trans-
ferred to nitrocellulose membrane. Incubation with anti-
Jak2oranti-Stat3antibodieswascarriedoutovernightat4◦C
followed bywashings andincubationwithaHRP-conjugated
secondary antibody. The same membranes were stripped,Journal of Signal Transduction 3
and protein expression for β-actin (protein loading control)
was determined. Protein bands were detected using chemi-
luminescencesubstrate (Pierce-Thermo Scientiﬁc,Rockford,
IL) and analyzed by image analysis (Image J Software,
National Institute of Health, Bethesda, MD). Results are
expressed as the ratio of Jak2/β-actin or Stat3/β-actin.
2.6.2.PhosphorylationofStat3. ThephosphorylationofStat3
was determined using a cell-based assay (SABiosciences,
Frederick, MD). Brieﬂy, human mesangial cells were seeded
into 96-well cell culture plates 24–48hr prior to the assay.
Cells were divided into two sets and treated with exogenous
Ang II or transfected with Ang II for 20 minutes after
which media were removed and cells were ﬁxed with 4%
formaldehyde/1x phosphate buﬀered saline (PBS) buﬀer.
After washes and blocking, one set of cells was incubated
f o r1 ha tr o o mt e m p e r a t u r ew i t hp h o s p h o - S t a t 3s e r i n e
727 or phospho-Stat3 tyrosine 705 antibodies to measure
phosphorylatedStat3,andtheothersetofcellswasincubated
with a pan-Stat3 antibody to measure total Stat3. This was
followed by incubation with a HRP-conjugated secondary
antibody for 1h at room temperature. The ﬁnal reaction was
developed with TMB and absorbance read at 450nm using
anELISAplatereader.Ineachwell, theantibodyreactionwas
normalized totherelativecellnumberwhich wasdetermined
usingacellstainingkit(SABiosciences).Resultsareexpressed
as the ratio of phospho-Stat3/total Stat3.
2.6.3. DNA Binding Activity of Stat3. Nuclear extracts from
mesangial cells were prepared and used for determination
of Stat3-DNA binding activity (Clontech Laboratories, Inc.,
CA).Inbrief,nuclearextractsampleswere incubatedina96-
well plate coated with oligonucleotides containing the con-
sensus DNAbinding sequencesfor Stat3transcription factor.
Stat3 present in the sample recognized and bound to the
speciﬁc consensus DNA sequence and the resulting DNA-
Stat3 complex was detected by incubating the samples with
a primary anti-Stat3 antibody followed by secondary incu-
bation with an HRP-conjugated antibody. The ﬁnal reaction
was developed with TMB and read at 450nm in an ELISA
plate reader. The absorbance readings (OD450) represented
binding activity of Stat3 transcription factor.
2.7. Statistical Analysis. Data were analyzed by Student’s t-
test and analysis of variance (ANOVA) (Instat, Graph-Pad,
San Diego, CA) followed by posttest comparisons between
groups. A P<0.05 was considered signiﬁcant. Values are
expressed asmean ±SEM,and“n”denotesnumberofexper-
iments in each group.
3.Results
3.1. Transfection of HumanMesangial Cells with Ang II. First,
the feasibility of transfecting primary human mesangial cells
with Ang II to increase intracellular Ang II levels using
proteojuice (Novagen, WI) was examined. Cells cultured in
Labtek chamber slides were incubated with Ang II labeled
with ﬂuorescein (Ang II-FITC) mixed with proteojuice for
30min and examined under epiﬂuorescence microscope
(Carl Zeiss MicroImaging Inc., NY). Figure 1 represents a
sample picture from one such experiment. Cells transfected
with Ang II-FITC showed presence of green ﬂuorescence (b)
compared to nontransfected cells (a). Also, cells pretreated
with 100μM candesartan (an Ang II receptor blocker) fol-
lowed by transfection with Ang II-FITC showed green ﬂuo-
rescence (c)similar tothatobservedin transfected cellswith-
out candesartan treatment (b). These observations suggested
that transfection of Ang II using proteojuice could deliver
Ang II intracellularly and that Ang II delivery by this method
is not aﬀected by treatment with AT1 receptor blocker.
To study speciﬁc eﬀects of intracellular Ang II on
mesangial cell functions, it was important to blockthe extra-
cellular Ang II signaling pathway activated by binding of any
free Ang II present in the proteojuice mixture to cell mem-
brane AT1 receptors. For this purpose, candesartan was cho-
sen because of its physical property of binding tightly to
AT1 receptor which prevents receptor activation and inter-
nalization [16].Therefore, inallfurtherexperiments,mesan-
gial cells were pretreated with candesartan (100μM) for 1h
and then transfected with Ang II (1μM) using proteojuice
transfection reagent. Candesartan was found to have no
eﬀect on proteojuice delivery of Ang II into mesangial cells
(Figure 1).
3.2.AngIIDelivery byProteojuiceIncreases Intracellular Levels
of Ang II. To determine optimum conditions for increasing
intracellular Ang II levels by the proteojuice transfection
method, mesangial cells were incubated with 10mM glucose
(NG) alone or NG containing proteojuice and 10−7–10−5 M
of Ang II (NG + t-Ang II) for 30min followed by measure-
ment of intracellular Ang II in cell lysates. Intracellular Ang
II levels increased with increasing concentrations of Ang II
in the proteojuice mixture showing ∼1.7-fold increase with
10−7 MA n gI I( Figure 2(a)). Also, increases of ∼5-fold and
∼10-fold in intracellular Ang II levels were observed with
10−6 Ma n d1 0 −5 M Ang II, respectively (Figure 2(a)).
In separate experiments, mesangial cells were incubated
with NG or NG containing 10−6 MA n gI Ia n dp r o t e o j u i c e
(NG + t-Ang II) mixture for 15min-2h. A 1.5-fold increase
in Ang II levels in the cell lysates (intracellular) was ob-
served after 15min of incubation (Figure 2(b)). Further, in-
tracellular Ang II levels were increased by ∼6-fold after
30min, ∼8-fold after 60min, and ∼9-fold after 120min,
(Figure 2(b)). These results showed a concentration- and
time-dependent increase in intracellular Ang II levels in re-
sponse to Ang II transfection in mesangial cells.
3.3. Intracellular Ang II Increases TGF-b1, Collagen IV, Fi-
bronectin andCell Proliferation. Next, the eﬀectsofincreased
intracellular Ang II levels on TGF-b1 and matrix proteins
suchascollagenIVandﬁbronectinwere determined.Mesan-
gial cells were incubated with 5mM glucose alone (NG;
control group) or NG containing a mixture of Ang II and
proteojuice (NG + t-Ang II; transfection group) for 24h,
and cell media were analyzed for TGF-b1, collagen IV, and
ﬁbronectin levels. In Ang II transfected cells (NG + t-Ang
II), TGF-b1 levels were signiﬁcantly increased compared
to control cells (NG + t-Ang II: 147 ± 6% versus NG:4 Journal of Signal Transduction
Ang II-FITC
(a)
Ang II-FITC + proteojuice
(b)
Ang II-FITC + proteojuice + candesartan
(c)
Figure 1: Transfection of human mesangial cells with Ang II using proteojuice. Human mesangialcells incubated for 30min with a mixture of
proteojuice and Ang II-FITC showed green ﬂuorescence (b) compared to cells that were incubated with Ang II-FITC alone (a). In addition,
cells incubated with proteojuice + Ang II-FITC and 100μM candesartan also showed green ﬂuorescence (c) suggesting that treatment with
Ang II receptor blocker does not interfere with intracellular delivery of Ang II by proteojuice.
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Figure 2: Eﬀect of Ang II transfection by proteojuice on intracellular Ang II levels. (a) Human mesangialcells transfected with Ang II (NG + t-
Ang II) showed a dose-dependent increase in intracellular Ang II levels with a 5-foldincrease at10−6 M Ang II concentration.NG represents
cells incubated with 10mM glucose alone. (b) In separate experiments, transfection of cells with 10−6 M Ang II raised intracellular Ang II
levels in a time-dependent fashion showing a 9-fold increase after 120min of incubation. Data are presented as mean ± SEM (n = 3). NG
represents the mean of pooled values corresponding to the 4 time points.
100 ± 3%; Figure 3) suggesting increased secretion of TGF-
b1inresponsetoelevatedintracellularAngIIlevels.InAngII
transfected cells, theincrease in TGF-b1was accompaniedby
increases in levelsofcollagen IV (NG + t-Ang II: 144 ± 18%)
and ﬁbronectin (NG + t-Ang II: 140 ± 14%) (Figure 3).
Additionally, increased intracellular Ang II levels in
Ang II-transfected cells (NG + t-Ang II) stimulated cell
proliferation compared to cells incubated in NG alone (NG
+ t-Ang II: 138 ± 4% versus NG: 100 ± 9%, P<0.05,
n = 5). Since Ang II-transfected cells were pretreated with
candesartan, these eﬀects of intracellular Ang II appear to
be mediated by intracellular signaling mechanisms diﬀerent
from the extracellular Ang II signaling pathway which is
activated via AT1 receptors present on the cell membrane.
3.4.Intracellular AngIISignaling: EﬀectonStat3Transcription
Factor. Since Stat3 transcription factor plays a key role in
Ang II-mediated growth eﬀects in mesangial cells [17], we
tested the eﬀect of intracellular Ang II on Stat3.
3.4.1. Stat3 Protein Expression. Mesangial cells were incu-
batedin 5mM glucose(NG;control)orNGcontaining 1μM
Ang II mixed with proteojuice (NG + t-Ang II) for 24h.
Prior to transfection with Ang II, cells were treated with
100μM candesartan for 1h to block cell membrane AT1
receptors. In these experiments, mesangial cells incubated
with 1μM exogenous Ang II alone (NG + ex-Ang II) or in
combinationwith100μMcandesartan (NG+C+ex-AngII)
were included as controls since exogenous Ang II is shownJournal of Signal Transduction 5
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Figure 3: Eﬀect of intracellular Ang II on TGF-b1, collagen IV, and
ﬁbronectin. Cell media from mesangial cells transfected with Ang
II (NG + t-Ang II) for 24h showed a signiﬁcant increase in TGF-
b1, collagen IV, and ﬁbronectin levels compared to cells incubated
in 5mM glucose (NG) alone. Data are presented as mean ± SEM
(n = 5).
∗P < 0.05 versus NG.
to activate Stat3 via AT1 receptors in these cells (17). After
24h of treatment, experiments were terminated, and total
cell lysates (RIPA buﬀer) were prepared. Protein expression
of total Stat3 was determined by Western blotting.
As shown in Figure 4(a), mesangial cells treated with
exogenous Ang II or transfected with Ang II showed
increased protein expression of Stat3 transcription factor.
Densitometry analysis of Western blots revealed a signif-
icant increase in Stat3 protein expression in cells treated
with exogenous Ang II which was blocked by candesartan
(Figure 4(b)). These observations are in agreement with
earlier reports showing activation of Stat3 by exogenous
Ang II via AT1 receptors [17]. In mesangial cells transfected
with Ang II (NG + t-Ang II), a signiﬁcant increase in Stat3
protein expression was observed in response to increased
levels of intracellular Ang II (Figure 4(b)). Because cells in
NG + t-Ang II group were treated with candesartan prior to
transfection with Ang II, these results suggest that the eﬀect
ofintracellular Ang IIon Stat3protein isnotmediated by the
AT1 receptor-linked extracellular signaling pathway.
3.4.2. Stat3 Phosphorylation. Mesangial cells were cultured
in 96-well plates and incubated with 5mM glucose (NG) or
NG containing 1μMA n gI Im i x e dw i t hp r o t e o j u i c e( N G+
t-Ang II) or NG with 1μMe x o g e n o u sA n gI I( N G+e x -
Ang II) for 20 minutes. At termination of the incubation
period, cells were ﬁxed and then assayed for levels of pStat3
ortotalStat3asdescribedinMethods.Mesangialcellstreated
with exogenous Ang II (NG + ex-Ang II) showed signiﬁcant
increases in phosphorylation of Stat3 at both serine 727
(NG + ex-Ang II: 1.17 ± 0.18 versus NG: 0.66 ± 0.03) and
tyrosine 705 residues (NG + ex-Ang II: 1.15 ± 0.19 versus
NG: 0.54 ± 0.08) (Figure 5). In contrast, Ang II-transfected
cells showed a signiﬁcant increase in Stat3 phosphorylation
at tyrosine 705residue (NG+ t-Ang II:1.0 ± 0.06versusNG:
0.54 ± 0.08) but not at serine 727 residue (NG + t-Ang II:
0.59 ± 0.2 versus NG: 0.66 ± 0.03) (Figure 5).
3.4.3. Stat3 Binding Activity. Since tyrosine 705 phosphory-
lation is required for Stat3 nuclear translocation and DNA
binding, theeﬀectofintracellular AngII onStat3DNAbind-
ing activity was examined. Mesangial cells were incubated
with 5mM glucose (NG), NG containing 1μMe x o g e n o u s ,
ortransfected with 1μM Ang IIfor 24h, and nuclear extracts
were prepared and assayed for Stat3 DNA binding activity.
A signiﬁcant increase in Stat3 DNA binding activity was
observed in mesangial cells treated with exogenous Ang II
(NG + ex-Ang II) or transfected with Ang II (NG + t-Ang II)
compared to NG control (NG + ex-Ang II: 128 ± 8%; NG +
t-Ang II: 126 ± 3%; NG: 100 ± 11%; n = 4; P<0.05 versus
NG). Thus, these results showed that intracellular Ang II
increased Stat3 phosphorylation (Tyr705) and DNA binding
activity as well.
3.5. Role of Jak2 in Intracellular Ang II-Induced Activation of
Stat3. Jak2, a cytosolic tyrosine kinase, is shown to cause
activation of the latent cytoplasmic transcription factor such
as Stat3 in mesangial cells [17]. For this reason, the role of
Jak2 in intracellular Ang II-induced activation of Stat3 was
investigated by utilizing Jak2 inhibitors such as AG-490 and
Jak inhibitor I. AG-490 was chosen because in mesangial
cells, it has been shown to inhibit Ang II-induced collagen
IV protein synthesis [18] and high-glucose-induced increase
in TGF-b1 and ﬁbronectin synthesis along with inhibition of
Stat3 tyrosine phosphorylation [19]. Jak inhibitor I is a more
selective inhibitor of Jaks with much less eﬀects on other
kinases (Calbiochem EMD Chemicals Inc., NJ).
3.5.1. Eﬀect of Jak2 Inhibition on Stat3 Protein Expression
Eﬀect of AG-490. Human mesangial cells were incubated
with 5mM glucose (NG; control) or NG containing 1μM
of exogenous Ang II (NG + ex-Ang II) or NG containing
1μMAngIImixedwith proteojuice(NG+t-AngII)for24h.
In separate groups, cells were coincubated with exogenous
Ang II or Ang II/proteojuice mixer and 10μM AG-490 for
24h. At termination of experiments, total cell lysates were
prepared and analyzed for Jak2 and Stat3 protein expression
byWesternblotting.AsshowninFigure 6(a),e x ogenousA ng
II increased Jak2 as well as Stat3 protein expression, whereas
intracellularAngIIincreased Stat3proteinwithoutany eﬀect
on Jak2. Densitometry analysis of Western blots showed a
signiﬁcant increase in Stat3 protein in cells treated with
exogenous Ang II or transfected with Ang II compared to
NGcontrols(Figure 6(b)). Treatment with AG-490 inhibited
exogenousAngII-inducedincreaseinStat3proteinbutfailed
to block increase in Stat3 protein expression in Ang II-
transfected cells (Figure 6(b)). These ﬁndings suggest that
the eﬀect of intracellular Ang II on Stat3 may be mediated
via a Jak2-independent mechanism.6 Journal of Signal Transduction
1234
Stat3 92kDa
β-actin 42kDa
1: 5mM glucose (NG)
3: NG + 100μM candesartan (C) + ex-Ang II
4: NG + transfection with 1μM Ang II (NG + t-Ang II)
2: NG + 1μM exogenous Ang II (NG + ex-Ang II)
(a)
∧
NG N G+e x -
Ang II
N G+C+
ex-Ang II
NG + t-
Ang II
∗
∗
0
0.4
0.8
1.2
s
t
a
t
3
/
β
-
a
c
t
i
n
(b)
Figure 4: Eﬀect of intracellular Ang II on Stat3 protein expression. (a) A sample picture of Western blot of total cell lysates from mesangial
cells incubated with exogenous Ang II (NG + ex-Ang II) or transfected with Ang II (NG + t-Ang II) for 24h showing Stat3 protein band
(92kDa) and b-actin (42kDa) (loading control). (b) Densitometry analysis revealed a signiﬁcant increase in Stat3 protein in cells treated
with exogenous Ang II (NG + ex-Ang II) which was blocked by candesartan (C). In Ang II transfected cells (NG + t-Ang II), Stat3 protein
expression increased signiﬁcantlysimilarto thatobserved in cells treated with exogenous Ang II.Data are presented asmean ±SEM(n = 5).
∗P < 0.05 versus NG;P<0.05 versus NG + ex-Ang II.
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Figure 5: Eﬀect of intracellular Ang II on Stat3 phosphorylation.
Mesangial cells incubated with 5mM glucose (NG) containing
1μMe x o g e n o u sA n gI I( N G+e x - A n gI I )f o r2 0m i n u t e ss h o w e d
a signiﬁcant increase in both tyrosine 705 and serine 727 Stat3
phosphorylationcompared to NG control. In contrast, transfection
of cells with 1μM Ang II (NG + t-Ang II) for 20 minutes increased
Stat3 phosphorylation only at tyrosine 705 but not at serine 727
residue. Data are presented as mean ± SEM (n = 3).
∗P < 0.05
versus NG.
Eﬀect of Jak Inhibitor I. To study the eﬀect of Jak inhibitor
I on intracellular Ang II-induced increase in Stat3 protein,
experiments were set up as described above for AG-490
except that 10μM Jak inhibitor I was added to the media of
cells incubated with 1μM exogenous Ang II (NG + ex-Ang II
or1μMAngIImixedwithproteojuice(NG+t-AngII).After
24h, experiments were terminated, and total cell lysates were
prepared and analyzed for Jak2 and Stat3 protein expression
by Western blotting. Both treatment with exogenous Ang II
ortransfectionwithAngIIincreasedStat3proteinexpression
in mesangial cells (Figure 7(a)). Densitometry analysis also
revealed an increase in Stat3 protein in cells treated with
exogenous Ang II or transfected with Ang II (Figure 7(b)).
Treatment with Jak2 inhibitor I failed to inhibit increase in
Stat3 protein in either exogenous Ang II-treated or Ang II-
transfected cells (Figure 7(b)). Also, there was no eﬀect of
Jak inhibitor I on Jak2 protein expression in cells treated
with exogenous Ang II or transfected with Ang II (Figures
7(a) and 7(b)). Since Jak inhibitor I primarily targets Jak1,
it is likely that it may not have any eﬀects on Jak2 in human
mesangial cells as suggested by these results.
3.5.2. Eﬀect of Jak Inhibition on Stat3 (Tyr705) Phosphory-
lation. In further experiments, the eﬀect of AG-490 or Jak
inhibitor I on intracellular Ang II-induced phosphorylation
of Stat3 (Tyr705) was determined. Mesangial cells were
incubated with 5mM glucose (NG) or NG containing 1μM
exogenous Ang II (NG + ex-Ang II) or NG containing 1μM
Ang II mixed with proteojuice (NG + t-Ang II). Also, cells
treated with exogenous Ang II or transfected with Ang II
were incubated with 10μM of either AG-490 or Jak inhibitor
I. After 20 minutes of incubation, cells were ﬁxed and
assayed for phosphorylated Stat3 (Tyr705) and total Stat3.
A signiﬁcant increase in Stat3 (Tyr705) phosphorylation
was observed in cells exposed to exogenous Ang II (ex-Ang
II) or transfected with Ang II (NG + t-Ang II) compared
to cells incubated in 5mM glucose (NG) alone (NG: 0.64
± 0.09; NG + ex-Ang II: 1.08 ± 0.12; NG + t-Ang II:
0.98 ± 0.06) (Figure 8). Treatment with AG-490 did not
inhibitintracellularAngII-inducedphosphorylationofStat3
(Tyr705) in Ang II-transfected cells, whereas exogenous Ang
II-initiated Stat3 (Tyr705) phosphorylation was signiﬁcantly
reduced in the presence of AG-490 (Figure 8). In contrast,
there was no eﬀect of Jak inhibitor I on Stat3 (Tyr 705)
phosphorylation in either exogenous Ang II-treated or Ang
II-transfected cells (Figure 8). These results suggest that
intracellular Ang II may use a Jak2-independent mechanismJournal of Signal Transduction 7
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Figure 6:Role of Jak2 in intracellular Ang II-induced activation of Stat3 in human mesangial cells.(a)Asamplepicture ofWesternblotanalysis
showing speciﬁc protein bands for Jak2 (130kDa), Stat3 (92kDa), and b-actin (42kDa) (loading control). (b) Densitometry analysis of
Western blots revealed a signiﬁcant increase in Jak2 and Stat3 protein expression in mesangial cells incubated with 1μMe x o g e n o u sA n gI I
(NG + ex-Ang II) for 24h. In contrast, transfection of cells with Ang II (NG + t-Ang II) for 24h increased Stat3 protein expression without
any eﬀect on Jak2. Treatment with AG-490 inhibited Jak2 and Stat3 in NG + ex-Ang II group but not in NG + t-Ang II group. Data are
presented as mean ± SEM (n = 3).
∗P < 0.05 versus NG;P<0.05 versus NG + ex-Ang II.
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Figure 7: Role of Jak2 in intracellular Ang II-induced activation of Stat3 in human mesangial cells. (a) A sample picture of Western blot anal-
ysis showing speciﬁc protein band for Jak2 (130kDa), Stat3 (92kDa), and b-actin (42kDa) (loading control). (b) Densitometry analysis of
Western blots revealed a signiﬁcant increase in Stat3 protein expression in mesangial cells incubated with 1μMe x o g e n o u sA n gI I( N G+
ex-Ang II) ortransfected with Ang II(NG + t-Ang II) for24h.Treatment with JakinhibitorI did notblockincrease in Stat3protein in either
N G+e x - A n gI Io rN G+t - A n gI Ig r o u p .D a t aa r ep r e s e n t e da sm e a n± SEM (n = 3).
∗P < 0.05 versus NG.
for Stat3 phosphorylation (Tyr705) in contrast to a Jak2-
dependent mechanism employed by exogenous (extracellu-
lar) Ang II.
4.Discussion
The main objective of the present study was to determine
whether intracellular Ang II could independently stimulate
TGF-b1 and mesangial matrix without involvement of the
extracellular Ang II signaling pathway. Cultured human me-
sangial cells were transfected with Ang II to increase intra-
cellular Ang II levels, while the extracellular Ang II pathway
was blocked by pretreatment of cells with candesartan, an
Ang II receptor antagonist. Candesartan was chosen due to
its physical property of tight binding to AT1 receptor which
traps the receptor at the membrane [16]a n dp r e v e n t sA T 1
receptor-linked activation of the signaling pathway. Our
results showed that transfection of mesangial cells with Ang
IIincreasedintracellularAngIIlevelsinaconcentration-and
time-dependent manner. Further, mesangial cells transfected
with Ang II showed stimulation of TGF-b1, collagen IV,
and ﬁbronectin secretion in response to increased levels of
intracellular Ang II. Also, mesangial cell proliferation was
increased in transfected cells due to elevated levels of intra-
cellular Ang II. Because these eﬀects of intracellular Ang II
were noted while cell membrane AT1 receptors were blocked8 Journal of Signal Transduction
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Figure 8: Eﬀect of Jak2 inhibition on intracellular Ang II-induced
tyrosine 705 (Tyr705) phosphorylation of Stat3. Incubation of
mesangial cells with 1μM exogenous Ang II (ex-Ang II) for 20
minutes increased (Tyr705) Stat3 phosphorylation compared to
control cells incubated in 5mM glucose (NG), and this increase
wasinhibitedbyAG-490.Incontrast,transfectionofmesangialcells
withAngIIfor20minutes(NG+t-AngII)increasedStat3(Tyr705)
phosphorylationwhichwasnotblockedbyAG-490.Treatmentwith
Jak inhibitor I had no eﬀect on Stat3 (Tyr705) phosphorylation in
cells treated with exogenous Ang II or transfected with Ang II. Data
are presented asmean ± SEM ofobservationsshownin parentheses
foreach group.
∗P < 0.05 versus NG;P<0.05 versus NG + ex-Ang
II.
by candesartan, our ﬁndings suggest that intracellular Ang II
could initiate physiological responses without involving ex-
tracellular Ang II signaling pathways which are activated by
the cell membrane AT1 receptors.
Most of the known eﬀectsof Ang II are induced by extra-
cellular Ang II via activation of AT1 receptors present on the
cell membrane [20]. The binding of Ang II to AT1 receptor
initiates many signaling events including activation (phos-
phorylation) of Jak tyrosine kinases and Stat family of latent
cytoplasmic transcription factors [17]. Ang II also stimulates
formation of Stat3 homo- and hetrodimers complexes that
translocate to the nucleus and bind to speciﬁc DNA motifs
resulting in activation of the early growth response gene
[21]. Several studies by Marrero and associates reported
that the phosphorylation of Jak2 and Stat3 by Ang II is
critical for Ang II-mediated growth eﬀects such as activa-
tion of TGF-b1, synthesis of matrix proteins, and cell
proliferation [17]. In the present study, an increase in Stat3
protein expression was found in mesangial cells treated with
exogenous (extracellular) Ang II as well as transfected with
Ang II (intracellular Ang II). In further experiments, the
increasedintracellularAngIIlevelsinAngII-transfected cells
was found to cause a signiﬁcant increase in phosphorylation
of Stat3 at tyrosine 705 (Tyr705) but not at serine 727
(Ser727) residue. This was in contrast to exogenous Ang
II which caused phosphorylation of Stat3 at both tyrosine
(Tyr705) and serine (Ser727) residues. Interestingly, Ang
II (exogenous) was also found to induce tyrosine and
serine phosphorylation of Stat3 in a study using other
cell systems [22]. The same study showed that Ang II-
induced phosphorylation of Stat3 at serine 727 is mediated
by activation of extracellular regulated kinases 1 and 2 (ERK
1/2) [22]. In mesangial cells transfected with Ang II, we
did not observe activation (phosphorylation) of ERK 1/2 in
response to increased intracellular Ang II levels (data not
shown) indicating that intracellular Ang II may not induce
Stat3 phosphorylation at serine 727 residue. In Ang II-
transfected cells, increased Stat3 phosphorylation (Tyr705)
was accompanied by a signiﬁcant increase in Stat3 DNA
binding activity. Because cells transfected with Ang II were
pretreated with candesartan, these ﬁndings suggest that in-
tracellular Ang II causes tyrosine 705 phosphorylation of
Stat3 independent of cell membrane AT1 receptors and
promote Stat3 DNA binding activity which is important for
activation of gene transcription.
The role of Jak2 in extracellular Ang II-induced acti-
vation and translocation of Stat3 is well documented [17].
Studies in other cell systems have demonstrated that Ang II
binding to AT1 receptor initiates a physical association be-
tween carboxyl terminal of AT1 receptor with Jak2, which
is a critical event for activation of Jak2 kinase [23]. Indeed,
in glomerular mesangial cells, exogenous (extracellular) Ang
II is shown to activate Jak2 resulting in tyrosine phos-
phorylation and nuclear translocation of Stat3 [18]. In the
present study, the role of Jak2 in intracellular Ang II-induced
phosphorylation of Stat3 was investigated, and mesangial
cells treated with exogenous Ang II were included as positive
controls. Treatment with AG-490, an inhibitor of Jak2, was
found to block Stat3 phosphorylation (Tyr705) in mesangial
cells exposed to exogenous Ang II in agreement with earlier
reports [18]. To our surprise, Jak inhibitor I failed to block
phosphorylation of Stat3 (Tyr705) in response to treatment
with exogenous Ang II. Whereas in mesangial cells, AG-490
is shown to inhibit the eﬀectof exogenousAng II oncollagen
IV synthesis [18] and high glucose on TGF-b1 synthesis and
Stat3 tyrosine 705 phosphorylation [19], not much is known
about the eﬀects of Jak2 inhibitor I in these cells. Treatment
with AG-490 in mesangial cells transfected with Ang II did
not block phosphorylation of Stat3 (Tyr705) suggesting that
a Jak2-independent mechanism may be involved in intracel-
lular Ang II-induced tyrosine 705 phosphorylation of Stat3.
Interestingly, in other cell system, Ang II-induced tyrosine
705 phosphorylation and nuclear translocation of Stat3 is
also shown to be mediated by c-Src, a nonreceptor kinase
[24]. However, the functional role of c-Src in intracellular
Ang II-induced Stat3 phosphorylation (Tyr705) in human
mesangial cells remains to be tested.
At present, not much is known on the mechanisms
by which intracellular Ang II can inﬂuence mesangial cell
functions. Recently, it is proposed that intracellular Ang II is
stored inendosomesand uponreleaseinto thecellcytoplasm
may increase production of reactive oxygen species (ROS) by
direct interaction with mitochondria [25]. Previous studies
have also suggested that Ang II could exert intracellular
eﬀectsby binding toitsreceptorspresent in variouscytoplas-
mic organelles including the nucleus [26]. Indeed, intracel-
lular Ang II is shown to cause calcium mobilization in renal
proximal tubular cells [27] and cell proliferation in ChineseJournal of Signal Transduction 9
hamster ovary cells [28] independent of cell membrane AT1
receptors. Studies have also reported the existence of intra-
cellular AT1 receptors in renal cortical nuclei [29]a n di n
renal cortex and medulla of rat kidney [30]. Moreover, in
isolated rat cortical nuclei, Ang II increased transcription of
TGF-b1 mRNA by activation of nuclear AT1 receptors [31];
whethersuchmechanism operatesinmesangial cellsremains
an open question.
In summary, the present study showed that intracellular
Ang II activates Stat3 via a Jak2-independent mechanism
in contrast to extracellular Ang II-induced Stat3 activation
which is mediated by Jak2. Since both pathways appear to
converge on Stat3 using diﬀerent routes, they could exert
synergistic eﬀects on activation of Stat3 transcription factor
resulting in a greater stimulation of gene transcription of
TGF-b1 and matrix proteins, especially under high-glucose
condition when both intracellular and extracellular levels of
Ang II are increased [14, 15]. It is noteworthy that intra-
cellular Ang II-initiated responses were observed in the
presence of candesartan, thus suggesting that ARBs are
unable to blockthe intracellular component ofAng II signal-
ing. This might also explain why these agents (ARBs) com-
monly used in clinical practice fail to completely block the
progression of diabetic nephropathy. It is not known yet
whether intracellular Ang II receptors are structurally iden-
tical to the cell membrane AT1 receptors or belong to a sub-
class of AT1 receptors which participate in the intracellular
Ang II and/or nuclear signaling. There is clearly a need for
further understanding of the intracellular Ang II receptors
and/or signaling mechanisms for more eﬀective control of
RAS activity in diabetes and for better treatment of diabetic
nephropathy.
Acknowledgment
Ms. Bilquis Basith is duly acknowledged for providing tech-
nical assistance in the present study. Thanks are also due
to AstraZeneca for the generous gift of candesartan CV-
11974. This work was supported by a BLR&D Merit award
(R. Singh) from the Oﬃce of Research and Development of
the Department of Veterans Aﬀairs.
References
[1] D. J. Leehey, A. K. Singh,and R. Singh, “Angiotensin II and its
receptors in the pathogenesis of diabetic nephropathy,” in The
Diabetic Kidney, P. Cortes and C. E. Mogensen,Eds., pp. 3–21,
Humana Press, New Jersey, NJ, USA, 2006.
[ 2 ]S .K a g a m i ,W .A .B o r d e r ,D .E .M i l l e r ,a n dN .A .N o b l e ,
“Angiotensin II stimulates extracellular matrix protein syn-
thesis through induction of transforming growth factor-
β expression in rat glomerular mesangial cells,” Journal of
Clinical Investigation, vol. 93, no. 6, pp. 2431–2437, 1994.
[ 3 ]R .S i n g h ,N .A l a v i ,A .K .S i n g h ,a n dD .J .L e e h e y ,“ R o l e
of angiotensin II in glucose-induced inhibition of mesangial
matrix degradation,” Diabetes, vol. 48, no. 10, pp. 2066–2073,
1999.
[4] V. Kolm, U. Sauer, B. Olgemoller, and E. Schleicher, “High
glucose-induced TGF-b1 regulates mesangial production of
heparin sulfate proteoglycan,” American Journal of Physiology,
vol. 270, pp. F812–F821, 1996.
[ 5 ] F .N .Z i y a d e h ,K .S h a r m a ,M .E r i c k s e n ,a n dG .W o l f ,
“Stimulationofcollagengeneexpressionandprotein synthesis
in murine mesangial cells by high glucose is mediated by
autocrine activation oftransforminggrowth factor-b,” Journal
of Clinical Investigation, vol. 93, no. 2, pp. 536–542, 1994.
[ 6 ]E .J .L e w i s ,L .G .H u n s i c k e r ,R .P .B a i n ,a n dR .D .R o h d e ,
“The eﬀect of angiotensin-converting-enzyme inhibition on
diabetic nephropathy,” New England Journal of Medicine,v o l .
329, no. 20, pp. 1456–1462, 1993.
[ 7 ]S .A n d e r s e n ,L .T a r n o w ,P .R o s s i n g ,B .V .H a n s e n ,a n dH .
H. Parving, “Renoprotective eﬀects of angiotensin II receptor
blockade in type 1 diabetic patients with diabetic nephrop-
athy,” Kidney International, vol. 57, no. 2, pp. 601–606, 2000.
[8] M. Igarashi,A. Hirata, Y. Kadomoto,and M.Tominaga,“Dual
blockade of angiotensin II with enalapril and losartan reduces
proteinuria in hypertensive patients with type 2 diabetes,”
Endocrine Journal, vol. 53, no. 4, pp. 493–501, 2006.
[ 9 ]M .C .L a n s a n g ,D .A .P r i c e ,L .M .B .L a ﬀel et al., “Renal
vascular responses to captopril and candesartan in patients
with type 1 diabetes,” Kidney International,v o l .5 9 ,n o .4 ,p p .
1432–1438, 2001.
[10] R. Singh, A. K. Singh, and D. J. Leehey, “A novel mechanism
for angiotensin II formation in streptozotocin-diabetic rat
glomeruli,” American Journal of Physiology, vol. 288, no. 6, pp.
F1183–F1190, 2005.
[ 1 1 ]M .N o d a ,T .M a t s u o ,H .N a g a n o - T s u g ee ta l . ,“ I n v o l v e m e n t
of angiotensin II in progression of renal injury in rats with
genetic non-insulin-dependent diabetes mellitus (Wistar fatty
rats),” Japanese Journal of Pharmacology, vol. 85, no. 4, pp.
416–422, 2001.
[12] R. Singh, A. K. Singh, N. Alavi, and D. J. Leehey, “Mechanism
ofincreased angiotensinII formationinglomerularmesangial
cells cultured in high glucose,” Journal of the American Society
of Nephrology, vol. 14, no. 4, pp. 873–880, 2003.
[ 1 3 ]D .J .L e e h e y ,M .A .I s r e b ,S .M a r c i c ,A .K .S i n g h ,a n dR .S i n g h ,
“Eﬀect of high glucose on superoxide in human mesangial
cells: role of angiotensin II,” Nephron, vol. 100, no. 1, pp. 46–
53, 2005.
[14] R. Singh and D. J. Leehey, “Eﬀect of ACE inhibitors on
angiotensin II in rat mesangial cells cultured in high glucose,”
Biochemical and Biophysical Research Communications,v o l .
357, no. 4, pp. 1040–1045, 2007.
[15] R. Singh, D. Choubey, J. Chen, and D. J. Leehey, “Inhibition
of intracellular angiotensin II blocks high glucose eﬀect on
mesangial matrix,” Regulatory Peptides, vol. 158, no. 1–3, pp.
103–109, 2009.
[ 1 6 ]F .L .P .F i e r e n s a ,P .M .L .V a n d e r h e y d e n ,C .R o g g e m a n ,J .D e
Backer, T. J. Thekkumkara, and G. Vauquelin, “Tight binding
of the angiotensin AT1 receptor antagonist,” Biochemical
Pharmacology, vol. 61, no. 10, pp. 1227–1235, 2001.
[17] M. B. Marrero, A. K. Banes-Berceli, D. M. Stern, and D. C.
Eaton, “Role of the JAK/STAT signaling pathway in diabetic
nephropathy,” American Journal of Physiology, vol. 290, no. 4,
pp. F762–F768, 2006.
[18] F. Amiri, S. Shaw, X. Wang et al., “Angiotensin II activation
of the JAK/STAT pathway in mesangial cells is altered by high
glucose,” Kidney International, vol. 61, no. 5, pp. 1605–1616,
2002.
[ 1 9 ]X .W a n g ,S .S h a w ,F .A m i r i ,D .C .E a t o n ,a n dM .B .M a r r e r o ,
“Inhibition of the JAK/STAT signaling pathway prevents the
high glucose-induced increase in TGF-b1 and ﬁbronectin10 Journal of Signal Transduction
synthesis in mesangial cells,” Diabetes, vol. 51, no. 12, pp.
3505–3509, 2002.
[20] R. Ardaillou, D. Chansel, C. Chatziantoniou, and J. Dussaule,
“Mesangial AT1 receptors: expression, signaling, and regula-
tion,” Journal of the American Society of Nephrology, vol. 10,
supplement 1, pp. S40–S46, 1999.
[21] C. D. McWhinney, R. A. Hunt, K. M. Conrad, D. E. Dostal,
and K. M. Baker, “The type I angiotensin II receptor couples
to Stat1 and Stat3 activation through Jak2 kinase in neonatal
rat cardiac myocytes,” Journal of Molecular and Cellular
Cardiology, vol. 29, no. 9, pp. 2513–2524, 1997.
[ 2 2 ]J .C h u n g ,E .U c h i d a ,T .C .G r a m m e r ,a n dJ .B l e n i s ,“ S t a t 3
serine phosphorylation by ERK-dependent and independent
pathways negatively modulates its tyrosine phosphorylation,”
Molecular and Cellular Biology, vol. 17, no. 11, pp. 6508–6516,
1997.
[23] M. S. Ali, P. P. Sayeski, L. B. Dirksen, D. J. Hayzer, M. B.
Marrero, andK. E. Bernstein, “Dependence on the motifYIPP
forthephysicalassociationofJak2kinasewiththeintracellular
carboxyl tail of the angiotensin II AT1 receptor,” Journal of
Biological Chemistry, vol. 272, no. 37, pp. 23382–23388, 1997.
[ 2 4 ]H .L i a n g ,V .J .V e n e m a ,X .W a n g ,H .J u ,R .C .V e n e m a ,
and M. B. Marrero, “Regulation of angiotensin II-induced
phosphorylation of Stat3 in vascular smooth muscle cells,”
J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 274, no. 28, pp. 19846–
19851, 1999.
[25] R. N. Re and J. L. Cook, “The mitochondrial component of
intracrineaction,”American JournalofPhysiology,vol.299,no.
3, pp. H577–H583, 2010.
[ 2 6 ]R .R e ,“ T h en a t u r eo fi n t r a c r i n ep e p t i d eh o r m o n ea c t i o n , ”
Hypertension, vol. 34, no. 4, pp. 534–538, 1999.
[ 2 7 ]J .L .Z h u o ,X .C .L i ,J .L .G a r v i n ,L .G .N a v a r ,a n dO .
A. Carretero, “Intracellular ANG II induces cytosolic Ca2+
mobilization by stimulating intracellular AT1 receptors in
proximal tubule cells,” American Journal of Physiology,v o l .
290, no. 6, pp. F1382–F1390, 2006.
[28] K. M. Baker and R. Kumar, “Intracellular angiotensin II
induces cell proliferation independent of AT1 receptor,” Amer-
ican Journal of Physiology, vol. 291, no. 5, pp. C995–C1001,
2006.
[29] H. Licea, M. R. Walters, and L. G. Navar, “Renal nuclear
angiotensinII receptors innormalandhypertensive rats,”Acta
physiologica Hungarica, vol. 89, no. 4, pp. 427–438, 2002.
[30] K. D. Pendergrass, D. B. Averill, C. M. Ferrario, D. I. Diz,
and M. C. Chappell, “Diﬀerential expression of nuclear AT1
receptors and angiotensin II within the kidney of the male
congenic mRen2.Lewis rat,” American Journal of Physiology,
vol. 290, no. 6, pp. F1497–F1506, 2006.
[31] X. C. Li and J. L. Zhuo, “Intracellular ANG II directly induces
in vitro transcription of TGF-b1, MCP-1, and NHE-3 mRNAs
inisolatedratrenalcorticalnucleiviaactivationofnuclearAT1
areceptors,” American Journal ofPhysiology,vol.294,no.4,pp.
C1034–C1045, 2008.